
Opinion|Videos|June 18, 2024
Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective
Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
How will the potential approval of ribociclib for early breast cancer change your treatment paradigms?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Orforglipron Reduces Body Weight Up to 14% in Women at Every Stage of Menopause
2
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
3
Managing Grade 1 CRS in Patients With Follicular Lymphoma on Bispecific Antibodies: Home vs Health Care Facility Referred
4
New Evidence Positions Finerenone as Foundational Therapy Across the CKD Spectrum
5

































































































































